RBC Capital Markets increased its price target on Celestica (NYSE:CLS) shares from $115.00 to $140.00 while maintaining an Outperform rating. Currently trading at $131.66, near its 52-week high, ...

RBC Capital analyst Kaan Peker maintained a Buy rating on Mineral Resources Limited (MALRF – Research Report) on January 30 and set a price ...

UBS analyst Susy Tibaldi updated the financial outlook for EssilorLuxottica SA (EL:FP) (OTC: OTC:ESLOY), increasing the price ...

Bonnici was a managing director at RBC and led several high-profile deals across infrastructure and technology during his ...

Imposing higher capital requirements on UBS as a systemically relevant bank will usher in higher costs for companies and ...

In a report released on January 30, Andrew Brooke from RBC Capital maintained a Buy rating on Serco Group plc (SRP – Research Report), with a ...

Brian McGill and Michael Hyser operate as Johns Creek Financial along with support-staff members Stacie Alexander and Alexis ...

FnPS unlocks the potential for truly digital business models within and between institutions and helps accelerate transformation towards digital capital markets. Request the whitepaper Not a product ...

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price target hoisted by equities researchers at UBS Group from $162.00 to $176.00 in a research note issued to investors on ...